Dr Suresh Beri | Additional Director of Polysaccharide Conjugate Vaccine
Serum Institue Of India

Dr Suresh Beri, Additional Director of Polysaccharide Conjugate Vaccine, Serum Institue Of India

At SII, Suresh is responsible for the development and scale up of Meningococcal A tetanus toxoid conjugate vaccine (MenAfriVac) and Haemophilus Influenzae type b tetanus toxoid conjugate vaccine. Technology transfer, process development, validations and setting up of cGMP facilities. He has also been part of an expert panel in WHO the finalization of specification of meningococcal A conjugate vaccine for human use.


Day Two 11th October, Human @ 09:10

Plenary discussion: Where is the global vaccine industry shifting to for new collaborations? Perspectives from emerging markets and Asia

  • The role of emerging markets in the global supply and demand for vaccines
  • What vaccine technologies and vaccine candidates are favourable?
  • Does it align with other philanthropy organisations?
  • The role of Public-Public Partnerships (P2Ps) in vaccine R&D for poverty related and neglected diseases (PRNDs)
  • Priorities for linking new vaccine development with public health in low and middle income countries

back to speakers